Delivery Order SPE2DB24D9144-SPE2DB25FCMUV
- Not listed
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order by the Defense Logistics Agency on September 17, 2025, for 1,000 unit vials of Kcentra, valued at approximately $69.7K. This firm fixed-price delivery order, with an ultimate completion date of October 8, 2025, was issued without a set-aside designation. The award represents a single delivery order under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order valued at $18,641.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 1,000 unit vials of Kcentra. This firm fixed-price delivery order, issued on July 28, 2025, with an ultimate completion date of August 18, 2025, carries no set-aside designation. The award falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under...
- The Defense Logistics Agency awarded a $7,296.00 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for 1,000 unit vials of Kcentra. The delivery order, issued on September 3, 2025, with an ultimate completion date of September 24, 2025, carries no set-aside designation. This award represents a delivery order issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $9,539.52 by the Defense Logistics Agency on August 18, 2025, for the supply of Kcentra 500 unit vials. The contract carries an ultimate completion date of September 9, 2025, and is not designated under any set-aside program. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with...
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $21,888.00 to DMS Pharmaceutical Group Inc. for the supply of Kcentra 500 unit vials. This delivery order, issued on August 6, 2025, with an ultimate completion date of August 27, 2025, is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which carries a total value of $499,999,999 and extends through November 2026. The delivery will be...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, has been awarded a delivery order valued at $3,307.52 for 1,000 units of Kcentra under a firm fixed-price contract with the Defense Logistics Agency's Medical Supply Chain. The award was issued on September 15, 2025, with an ultimate completion date of October 10, 2025. This delivery order carries no set-aside designation and represents performance at the contractor's Park...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a firm fixed-price delivery order valued at $3,477.76 by the Defense Logistics Agency (DLA) on August 21, 2025. The contract calls for the delivery of 1,000 unit vials of Kcentra, a vitamin K-dependent clotting factor concentrate used in medical treatment. This delivery order was issued without a set-aside designation and carries an ultimate completion date of...
- DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a delivery order on July 25, 2025, by the Defense Logistics Agency (DLA) for 1,000 unit vials of Kcentra, a vitamin K-dependent clotting factor concentrate used to reverse anticoagulation. The firm fixed-price delivery order has a ceiling value of $19,845.12 with an ultimate completion date of August 15, 2025. This award was issued without a set-aside designation,...
- The Defense Logistics Agency awarded a delivery order valued at $39,520 to DMS Pharmaceutical Group Inc. for 1,000 unit vials of Kcentra, a vitamin K-dependent clotting factor complex used for rapid reversal of warfarin anticoagulation. This firm fixed-price delivery order, issued on August 12, 2025, with ultimate completion by September 3, 2025, represents a discrete purchase under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with DLA valued at $500 million through November...
- The U.S. Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth $9,977.28 to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract is for the delivery of 500-unit vials of Kcentra, a blood coagulant medication, with a performance period ending on April 12, 2024. This delivery order is issued under DMS Pharmaceutical Group's existing indefinite delivery contract with DLA, valued at up to $4,999,999, which enables...
- SPE2DB24D9144Indefinite Delivery Contract
- SPE2DB24D9144-SPE2DB25FCMUVDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $13,546.24 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of 500-unit vials of Kcentra. The delivery order, issued on June 18, 2025, with an ultimate completion date of July 11, 2025, employs firm fixed-price pricing with no set-aside designation. This delivery order falls under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the DLA under the SPE2DB program, a $500 million vehicle valid through November 2026 that enables the agency to procure a comprehensive range of pharmaceutical products supporting military healthcare facilities. Kcentra is a prothrombin complex concentrate used primarily for urgent reversal of warfarin anticoagulation in emergency settings. DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, consistently securing contracts for diverse pharmaceutical products including biologics, specialty medications, and medical consumables. The company's federal contracting history demonstrates sustained capability in delivering complex pharmaceutical products directly to Department of Defense healthcare sites nationwide, positioning it as a reliable partner for DLA's medical supply requirements.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $13.5k | 6/18/25 |